Physician profile
Sami A Raphael
NPI 1790871846
$9,286.46
in general payments reported to CMS, 2019-2025
49 companies · $22.44 in 2025
The $22.44 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,219 · 2020: $1,143 · 2021: $2,292 · 2022: $2,341 · 2023: $1,218 · 2024: $51.04 · 2025: $22.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,144.62 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,131.05 | 2019-2023 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $843.86 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $714.66 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $564.27 | 2019-2023 | |
| Novo Nordisk INC | $402.30 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $391.72 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $390.00 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $364.99 | 2019-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $351.99 | 2021-2023 | Hetlioz |
| Janssen Pharmaceuticals, INC | $339.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $335.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $285.97 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $278.80 | 2019-2023 | Seglentis, Livalo |
| Abbvie INC. | $221.33 | 2022-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.